OraSure Technologies (OSUR) : Zacks Investment Research ranks OraSure Technologies (OSUR) as 3, which is a Hold recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 2 research analysts is 2, which indicates as a Buy.
OraSure Technologies, Inc. has dropped 0.43% in the last five trading days, however, the shares have posted positive gains of 7.53% in the last 4 weeks. OraSure Technologies, Inc. has dropped 2.37% during the last 3-month period . Year-to-Date the stock performance stands at 8.7%. OraSure Technologies (NASDAQ:OSUR): stock turned positive on Tuesday. Though the stock opened at $7.03, the bulls momentum made the stock top out at $7.1 level for the day. The stock recorded a low of $6.99 and closed the trading day at $7, in the green by 0.14%. The total traded volume for the day was 563,154. The stock had closed at $6.99 in the previous days trading.
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test, OraQuick ADVANCE, OraSure HIV-1 oral specimen collection device, OraQuick HCV rapid antibody test, Intercept oral fluid drug testing system, OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary, DNA Genotek Inc., the Company provides oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.